Hoe verhoudt BOD's PS Ratio zich tot zijn concurrenten?

BOD is een goede waarde op basis van zijn Price-To-Sales Ratio (1.3x) vergeleken met het gemiddelde van gelijken (1.5x).

Hoe verhoudt BOD's PS Ratio zich tot andere bedrijven in de AU Pharmaceuticals industrie?

BOD is een goede waarde op basis van de Price-To-Sales -ratio ( 1.3 x) vergeleken met het Australian Pharmaceuticals -industriegemiddelde ( 4.9 x).

Wat is BOD's PS Ratio vergeleken met zijn Fair PS Ratio? Dit is de verwachte PS Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

Onvoldoende gegevens om de Price-To-Sales Fair Ratio van { BOD te berekenen voor waarderinganalyse.

Wat is de reële prijs van BOD als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

Onvoldoende gegevens om de reële waarde van BOD te berekenen voor waarderingsanalyse.

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Er zijn onvoldoende gegevens om een prijsvoorspelling te tonen.

Bod Science (CHIA:BOD) - Aandelenkoers, Nieuws & Analyse

BOD Overzicht aandelen

Bod Science Limited operates as a cannabis focused drug development and product innovation company in Australia, the United Kingdom, the European Union, and the United States. Meer informatie

BOD fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	2/6
Dividenden	0/6

Risicoanalyse

Heeft geen betekenisvolle marktkapitalisatie ( A$4M )

Aandelen zijn zeer illiquide

De winst is de afgelopen 5 jaar met 4.2% per jaar gedaald

Negatief eigen vermogen

+ 2 meer risico's

Bod Science Limited Concurrenten

Avecho Biotechnology

ASX:AVE

AU$6.3m

Cann Global

ASX:CGB

AU$5.4m

Epsilon Healthcare

ASX:EPN

AU$7.2m

Argent BioPharma

ASX:RGT

AU$13.6m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Bod Science
Historische aandelenkoersen
Huidige aandelenkoers	AU$0.024
52 Week Hoogtepunt	AU$0.13
52 Week Laag	AU$0.024
Bèta	1.45
11 maand verandering	0%
3 maanden verandering	-7.69%
1 Jaar Verandering	-64.18%
33 jaar verandering	-94.95%
5 jaar verandering	-94.84%
Verandering sinds IPO	-91.43%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	BOD	AU Pharmaceuticals	AU Markt
7D	0%	-7.0%	1.2%
1Y	-64.2%	34.9%	19.7%

Rendement versus industrie: BOD presteerde slechter dan de Australian Pharmaceuticals -sector, die het afgelopen jaar een rendement van 34.9 % opleverde.

Rendement versus markt: BOD presteerde slechter dan Australian Market, dat het afgelopen jaar een rendement van 19.7 % opleverde.

Prijsvolatiliteit

Is BOD's price volatile compared to industry and market?
BOD volatility
BOD Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	11.8%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.5%
10% least volatile stocks in AU Market	3.2%

Stabiele aandelenkoers: De aandelenkoers van BOD is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van BOD in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2014	n/a	Jo Patterson	bodscience.com

Bod Science Limited Samenvatting

Hoe verhouden de winst en inkomsten van Bod Science zich tot de beurswaarde?
BOD fundamentele statistieken
Marktkapitalisatie	AU$4.26m
Inkomsten(TTM)	-AU$7.95m
Inkomsten(TTM)	AU$3.32m

1.3x

P/S-verhouding

-0.5x

Koers/Winstverhouding

Is BOD overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
BOD resultatenrekening (TTM)
Inkomsten	AU$3.32m
Kosten van inkomsten	AU$1.05m
Brutowinst	AU$2.27m
Overige uitgaven	AU$10.22m
Inkomsten	-AU$7.95m

Laatst gerapporteerde inkomsten

Jun 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.045
Brutomarge	68.40%
Nettowinstmarge	-239.47%
Schuld/Eigen Vermogen Verhouding	-136.9%

Hoe presteerde BOD op de lange termijn?

Bekijk historische prestaties en vergelijking

BOD Overzicht aandelen

Risicoanalyse

Bod Science Limited Concurrenten

ASX:AVE

AU$6.3m

ASX:CGB

AU$5.4m

ASX:EPN

AU$7.2m

ASX:RGT

AU$13.6m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Bod Science Limited announced that it expects to receive AUD 2.05 million in funding

Bod Science Limited has filed a Follow-on Equity Offering in the amount of AUD 2.05 million.

Bod Science Limited announced that it expects to receive AUD 2.05 million in funding

No independent directors

Bod Science Limited has completed a Follow-on Equity Offering in the amount of AUD 1.93008 million.

Bod Science Limited, Annual General Meeting, Nov 27, 2023

Recent updates

Bod Science Limited announced that it expects to receive AUD 2.05 million in funding

Bod Science Limited has filed a Follow-on Equity Offering in the amount of AUD 2.05 million.

Bod Science Limited announced that it expects to receive AUD 2.05 million in funding

No independent directors

Bod Science Limited has completed a Follow-on Equity Offering in the amount of AUD 1.93008 million.

Bod Science Limited, Annual General Meeting, Nov 27, 2023

Full year 2023 earnings released: AU$0.056 loss per share (vs AU$0.051 loss in FY 2022)

New major risk - Negative shareholders equity

New minor risk - Financial data availability

New major risk - Shareholder dilution

Bod Australia Limited (ASX:BOD) completed the acquisition of Aqua Phase Ltd.

No independent directors

No independent directors

First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.02 loss in 1H 2022)

Bod Science Limited Announces Company Secretary Changes

Less than half of directors are independent

Bod Australia Limited Provides Statistical Summary from Its Phase 1 Cannabidiol (CBD) Pharmacokinetic (PK) Study

Bod Australia Limited Announces Resignation of Hanno Cappon as Non-Executive Director

Less than half of directors are independent

Bod Australia Limited, Annual General Meeting, Nov 28, 2022

Less than half of directors are independent

Less than half of directors are independent

Bod Australia Limited to Launch a New Medicinal Cannabis Product to the Australian Market in July

Less than half of directors are independent

Bod Australia Limited Completes A Proof of Concept Study into the Safety and Efficacy of A Cannabigerol (CBG) Dominant Cannabis Extract Which Has Shown Very Promising Results

Bod Australia Limited Completes A Proof of Concept Study into the Safety and Efficacy of A Cannabigerol (CBG) Dominant Cannabis Extract Which Has Shown Very Promising Results

Bod Australia Limited Announces Board Changes

Bod Australia Limited Advises That It Has Successfully Enrolled First Patients for Its Australian-Based Planned Phase Iib Clinical Trial

Less than half of directors are independent

Bod Australia Limited Announces First Patients Enrolled for Long-Covid Study Investigating the Efficacy of CBD- Dominant Medicinal Cannabis

Bod Australia Announces Board Changes

First half 2022 earnings: Revenues and EPS in line with analyst expectations

High number of new and inexperienced directors

Bod Australia Limited's Novel Food Application Accepted by UK Food Service Agency

High number of new and inexperienced directors

Bod Australia Limited Announces Ethics Approval Received for Schedule 3 Clinical Trial

Bod Australia Limited Announces Secures Clinical Trial Authorisation from the United Kingdom's Medicines & Healthcare Products Regulatory Agency

High number of new and inexperienced directors

Bod Australia Limited Provides Revenue Guidance for the Fiscal Year 2022

Full year 2021 earnings released: AU$0.043 loss per share (vs AU$0.054 loss in FY 2020)

Bod Australia Limited Launches New CBD -Based Products

Bod Australia Limited Provides Update on New Medicinal Cannabis Product Launch

Chief Financial Officer has left the company

New 90-day low: AU$0.41

Bod Australia Limited Announces the Resignation of Charles Altshuler as Chief Financial Officer, Effective 31 March 2021

New 90-day low: AU$0.42

Bod Australia Limited announced that it expects to receive AUD 8 million in funding

Bod Australia Limited Receives AUD 200,000 Binding Purchase Order from Exclusive Global Partner

New 90-day high: AU$0.58

Bod Australia Limited Announces Strong Growth in Medicinal Cannabis Sales Continues

Bod Australia Limited Launches CBD Products in the Netherlands

Bod Australia Limited Undertakes a Phase I Trial of the Safety Tolerability and Pharmacokinetics of Cannabidiol, Administered in Healthy Volunteers Across Multiple Formulations

New 90-day high: AU$0.51

New 90-day high: AU$0.40

New 90-day high - AU$0.32

Full year earnings released - AU$0.054 loss per share

New 90-day low - AU$0.26

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf